New hope for Tough-to-Treat blood cancer: boosting CAR-T therapy with added drugs
NCT ID NCT06940297
Summary
This study is testing whether adding two drugs, dasatinib and quercetin, to a standard CAR-T cell therapy regimen works better for patients with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see if this combination helps the CAR-T cells kill more cancer cells and leads to a deeper, longer-lasting response. The study will enroll 44 adults who have already tried at least three other types of treatment for their myeloma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.